- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05326243
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
A Phase 1/2 Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of CD19-targeted Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) Therapy in Patients With Relapsed or Refractory B-cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cluster of differentiation (CD) 19 chimeric antigen receptor T-cell (CAR-T) has been a very promising treatment option for multiple types of B-cell lymphoma. Kymriah® (tisagenlecleucel, Novartis) and Yescarta® (axicabtagene ciloleucel, Gilead) were licensed by the United States Food and Drug Administration (US FDA) and European Medicines Agency (EMA) in 2017 to treat relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), and High-grade B-cell lymphoma (HGBCL). A third anti-CD19 CAR-T product, Tecartus (brexucabtagene autoleucel, Gilead) was approved by the US FDA for relapsed and refractory mantle cell lymphoma (MCL) in July 2020. In February 2021, another product, Breyanzi® (lisocabtagene maraleucel, Juno Therapeutics, Inc.), was approved by the US FDA for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, Primary mediastinal large B cell lymphoma (PMLBCL), and Gr. 3b FL.
Currently, in Taiwan, no CD19 CAR-T therapies are available commercially.This Phase 1/Phase 2 study will test PL001, a CD19 CAR-T therapy manufactured by Pell Bio-Med Technology Co., Ltd., as a monotherapy for relapsed or refractory B-cell lymphoma. The Phase 1 of the study will be conducted to establish a dose range that is well tolerated by the majority of patients and to provide a safety profile of PL001 in the target patient population. The results of the Phase 1 of the study will recommend the dose selection for the Phase 2 of the study. Phase 2 of the study will assess the efficacy and safety of PL001 in patients with relapsed or refractory B cell lymphoma.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Cherry Lo, MSC
- Phone Number: 3111 886-2-8791-1789
- Email: cherry.lo@pellbmt.com
Study Locations
-
-
-
Kaohsiung, Taiwan, 807377
- Recruiting
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Principal Investigator:
- Shyh-Shin Chiou
-
Taipei, Taiwan, 100225
- Recruiting
- National Taiwan University Hospital
-
Principal Investigator:
- Shang-Ju Wu
-
Taipei, Taiwan, 112201
- Recruiting
- Taipei Veterans General Hospital
-
Principal Investigator:
- Liang-Tsai Hsiao
-
Taipei city, Taiwan, 11031
- Not yet recruiting
- Taipei Medical University - Taipei Medical University Hospital
-
Principal Investigator:
- Jyh-Pyng Gau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Screening 1:
- Patient is 14 to 70 years of age, inclusive, at the time of signing the informed consent.
- Histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMLBCL), large B-cell lymphoma transformed from follicular lymphoma (FL), or grade 3a or 3b FL.
- On-site documentation of CD19 on the dominant population of cancer cells.
Disease status should meet any one of the below:
- Patients with previous autologous-hematopoietic stem cell transplantation (auto HSCT) have relapsed, progressive, or refractory disease (defined as having not achieved a CR) after transplantation regardless of lines of systemic therapy.
- Patients without previous HSCT have relapsed, progressive, or refractory disease (defined as having not achieved a CR) after at least 2 lines of systemic therapy, including anti-CD20 antibody and anthracycline.
- Have no available effective systemic therapy as judged by the Investigator.
- At least one measurable non-CNS (central nervous system) lesion based on Lugano classification for lymphoma.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Life expectancy of at least 3 months.
- Patient is male or female.
A male patient must agree to use a highly effective contraception as detailed in Section 10.4 (Appendix 4) during the treatment period and for at least 2 years after the dose of PL001 and refrain from donating sperm during this period.
Female Patients:
A female patient is eligible to participate if she is not pregnant (Section 10.4; Appendix 4), not breastfeeding, and at least one of the following conditions applies:
• Not a woman of childbearing potential (WOCBP) as defined in Section 10.4 (Appendix 4).
OR
• A WOCBP who agrees to follow the contraceptive guidance in Section 10.4 (Appendix 4) during the treatment period and for at least 2 years after the dose of PL001 and refrain from donating ova during this period.
- Patient/patient's parent/legal guardian is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Screening 2:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- CAR-T is successfully manufactured and ready for use, from cells harvested by non mobilized leukapheresis.
- WOCBP who have a negative serum pregnancy test at Screening 2.
Exclusion Criteria:
Screening 1:
- Chronic lymphocytic leukemia with Richter's transformation.
- Primary CNS lymphoma. (Non-primary CNS lymphoma with CNS involvement is eligible).
- Primary intra-ocular lymphoma.
- Prior CD19 targeted therapy, such as CAR-T, Bi-specific T-cell engagers (BiTE), or monoclonal antibody.
- History of cancers (includes myelodysplastic syndrome) other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless disease-free without active treatment for at least 3 years.
- History of allogeneic HSCT.
- History of autologous HSCT within 3 months prior to consent.
- Received any investigational product within 4 weeks prior to consent.
- Systemic anticancer therapy within 3 weeks prior to apheresis.
Long-term use of systemic corticosteroids, defined as daily use >10 mg of prednisolone or equivalent, within 2 weeks prior to leukapheresis.
Exception examples:
- Nasal, ophthalmic, inhaled, intra-articular, and topical steroid preparation.
- Short term systemic steroid for drug, contrast, or blood transfusion allergic reaction management.
- Low dose maintenance steroid therapy for other conditions (e.g., asthma).
- Use of long-acting and short-acting myeloid growth factor within 2 weeks, 5 days prior to leukapheresis, respectively.
- Received anti-thymocyte globulin within 4 weeks prior to consent.
- Intrathecal chemotherapy within 1 week prior to leukapheresis.
Inadequate major organ functions at Screening, which were defined as any of below:
- absolute neutrophil count (ANC) <500/µL
- Absolute lymphocyte count (ALC) <300/µL, excluding leukemic cells.
- Hemoglobin (Hb) <8.0 g/dL
- Platelet count <75,000/µL without transfusion support within 3 days
- e. Baseline O2 saturation <92% by pulse oximetry at room air
- Significant CNS diseases such as dementia, major stroke, seizure while under antiepileptic drug
- Aspartate aminotransferase (AST) >5 × upper limit of normal (ULN) and alanine aminotransferase (ALT) >5 × ULN, or total bilirubin >2 × ULN (except for constitutional jaundice)
- Estimated glomerular filtration rate (eGFR) <60 mL/min as calculated by Cockcroft-Gault formula with overweight adjustment
- Significant cardiac disease including but not limited to: left ventricular ejection fraction (LVEF) <50%, QTc(the corrected QT interval) > 480 msec based on Fredericia's formula, clinically significant arrhythmias, history of myocardial infarction or unstable angina within 3 months prior to consent.
- Active hepatitis B virus (HBV) infection defined as detectable HBV DNA (Patients with positive anti-hepatitis B core antibody [HBcAb] must consent to regular monitoring of HBV DNA, and anti-HBV prophylaxis with oral anti-viral agent (such as entecavir) is mandatory until End-of-Study visit [Visit 15].)
- Active hepatitis C virus (HCV) infection defined as positive anti- HCV antibody plus detectable HCV RNA.
- Positive for human immunodeficiency virus (HIV) or human T-cell lymphotropic virus (HTLV) infection.
- Uncontrolled acute life-threatening bacterial, viral, or fungal infection (e.g., the need for intravenous therapeutic antibiotics, blood culture positive ≤72 hours prior to apheresis).
21. Any medical conditions which might compromise the patient's safety from leukapheresis, lymphodepletion chemotherapy, or CAR-T therapy and anticipated AEs, according to the Investigator's evaluation.
22.Patients with insufficient leukapheresis cells.
Screening 2:
Inadequate major organ functions at Screening which were defined as any of below:
- ANC <500/µL
- Hb <8.0 g/dL
- Platelet count <50,000/µL, without transfusion support within 3 days
- Baseline O2 saturation <92% by pulse oximetry on room air
- AST >5 × ULN and ALT>5 × ULN, or total bilirubin >2 × ULN (except for constitutional jaundice)
- Significant CNS diseases such as dementia, major stroke, seizure while under antiepileptic drug
- eGFR <60 mL/min as calculated by Cockcroft-Gault formula with overweight adjustment
Long-term use of systemic corticosteroids, defined as daily use >10 mg of prednisolone or equivalent.
Exception examples:
- Nasal, ophthalmic, inhaled, intra-articular, and topical steroid preparation.
- Short term systemic steroid for drug, contrast, or blood transfusion allergic reaction management.
- Low dose maintenance steroid therapy for other conditions (e.g., asthma).
- Use of long-acting and short-acting myeloid growth factor within 12 days, 2 days prior to lymphodepletion therapy, respectively.
- Uncontrolled acute life-threatening bacterial, viral, or fungal infection (e.g. the need for intravenous therapeutic antibiotics, blood culture positive ≤72 hours prior to lymphodepletion).
- Any medical condition which might compromise the patient's safety because of lymphodepletion chemotherapy or CAR-T therapy and anticipated AEs, according to the Investigator's opinion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CD19-targeted chimeric antigen receptor T-cell
Patients will receive a lymphodepletion chemotherapy with fludarabine plus cyclophosphamide for three consecutive days(Day -5 to Day -3) before infusion of CD19-targeted chimeric antigen receptor T-cell (CD19 CAR-T).
Patients will receive the CD19 CAR-T(also known as PL001) infusion on Day 0.
|
Drug: Fludarabine patients will receive a lymphodepletion chemotherapy with Fludarabine 25 mg/m2/day IV for 3 days on Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3). Drug: Cyclophosphamide patients will receive a lymphodepletion chemotherapy with cyclophosphamide 300 mg/m2/day IV for 3 dys Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3). Biological: CD19 CAR-T CD19 CAR-T cells will be administered using as a single dose at 0.1-9*10^6 cells/kg on Day 0 after completion of the lymphodepletion chemotherapy. The body weight calculated for PL001 dose is the actual body weight on the day of leukapheresis.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: Dose-limiting toxicities
Time Frame: 30 days
|
Dose-limiting toxicities through 30 days after PL001 infusion
|
30 days
|
Phase 2: best overall response (BOR)
Time Frame: 12 months
|
The BOR comprising of patients with partial and complete responses according to Lugano criteria assessed by the Independent Central Review.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1 and Phase 2: Treatment-related adverse events
Time Frame: 12 months
|
Treatment-related adverse events assessed by CTCAE v 5.0.
Overall grading of Cytokine Release Syndrome, immune effector cell associated neurotoxicity syndrome, based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria.
|
12 months
|
Phase 1 and Phase 2: Best overall response (BOR)
Time Frame: 12 months
|
The BOR of patients with partial and complete responses according to Lugano criteria assessed by the Investigator.
|
12 months
|
Phase 1 and Phase 2: Median duration of response (mDOR)
Time Frame: 12 months
|
Median duration of response (mDOR) measured from the time of initial documented response (complete response or partial response) until documented disease progression or death.
|
12 months
|
Phase 1 and Phase 2: Progression-free survival (PFS)
Time Frame: 12 months
|
Progression-free survival (PFS) defined as the time from the infusion of PL001 until objective disease progression or death, whichever occurs first.
|
12 months
|
Phase 1 and Phase 2: Overall survival (OS)
Time Frame: 12 months
|
Overall survival (OS) defined as the time from the infusion of PL001 until death from any cause.
|
12 months
|
Phase 1 and Phase 2: the health-related quality of life (HRQoL)
Time Frame: 12 months
|
Change in the health-related quality of life (HRQoL) by FACT-Lym (the Functional Assessment of Cancer Therapy-Lymphoma)® version 4
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1 and Phase 2: Pharmacokinetic (PK) profile of PL001-Persistence of PL001 by flow cytometry
Time Frame: 12 months
|
Persistence of PL001 in peripheral blood using flow cytometry
|
12 months
|
Phase 1 and Phase 2: Pharmacokinetic (PK) profile of PL001-Persistence of PL001 by qPCR
Time Frame: 12 months
|
PL001 transgene levels by qPCR (quantitative polymerase chain reaction) in peripheral blood
|
12 months
|
Phase 1 and Phase 2: Quality assurance of the product
Time Frame: [From start of CAR-T manufacturing to CAR-T infusion, estimated to be 45 days]
|
Rates for successful production and infused patients
|
[From start of CAR-T manufacturing to CAR-T infusion, estimated to be 45 days]
|
Phase 1 and Phase 2: To assess the cytokine biomarkers
Time Frame: 12 months
|
Cytokine concentrations in peripheral blood
|
12 months
|
Collaborators and Investigators
Investigators
- Study Chair: Chen-Lung Lin, MD, Pell Bio-Med Technology Co., Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PL001-NHL-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Large B Cell Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on CD19-targeted chimeric antigen receptor T-cell
-
Zhejiang UniversityInnovative Cellular Therapeutics Co., Ltd.Unknown
-
Shanghai Ming Ju Biotechnology Co., Ltd.RecruitingMantle Cell LymphomaChina
-
Shanghai Ming Ju Biotechnology Co., Ltd.RecruitingLymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell LymphomaChina
-
Shanghai Ming Ju Biotechnology Co., Ltd.RecruitingLymphoma, Non-Hodgkin | Diffuse Large B Cell LymphomaChina
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.RecruitingEarly Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune DiseasesSystemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathies | Primary Sjögren Syndrome | IgG4 Related DiseaseChina
-
Peking UniversityGracell Biopharmaceuticals, Inc.RecruitingGastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaChina
-
Cellular Biomedicine Group Ltd.Tianjin Medical University Cancer Institute and HospitalUnknownRefractory or Relapsed B-cell Non-Hodgkin LymphomaChina
-
Cellular Biomedicine Group Ltd.Shanghai Tongji Hospital, Tongji University School of MedicineUnknownRefractory or Relapsed Non-Hodgkin LymphomaChina
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial HospitalRecruiting
-
Seattle Children's HospitalActive, not recruitingCD 19+ Acute LeukemiaUnited States